Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. (Q37178600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

case report

0 references

title

Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Andreas Wicki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Tobias Buser

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Niels Willi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sacha I Rothschild

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Peter Schiller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Gieri Cathomas

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Alfred Zippelius

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Kirsten D Mertz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

16 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

Journal for Immunotherapy of Cancer

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

21 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Nivolumab in previously untreated melanoma without BRAF mutation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Ipilimumab in patients with cancer and the management of dermatologic adverse events

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Management of immune-related adverse events and kinetics of response with ipilimumab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Grover disease (transient acantholytic dermatosis).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Grover's disease: clinicopathologic review of 72 cases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

The spectrum of cutaneous disease in leukemias.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986338

Transient acantholytic dermatosis induced by recombinant human interleukin 4

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27532022

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

First report of ipilimumab-induced Grover disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27532022

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Transient acantholytic dermatosis (Grover's disease) in a patient with progressive systemic sclerosis treated with D-penicillamine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27532022

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S40425-016-0151-Z

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27532022%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

PubMed publication ID

27532022

1 reference